Exencial Wealth Advisors LLC Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

Exencial Wealth Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,504 shares of the company’s stock after selling 1,091 shares during the period. Exencial Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,820,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 1.5% during the 1st quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock valued at $5,100,421,000 after buying an additional 572,077 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 32,846,195 shares of the company’s stock valued at $4,791,274,000 after buying an additional 1,021,877 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Johnson & Johnson by 10.8% during the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after buying an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Johnson & Johnson by 7.7% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after purchasing an additional 2,118,870 shares during the period. Finally, Norges Bank purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $4,139,107,000. 68.51% of the stock is currently owned by institutional investors.

Johnson & Johnson stock traded up $0.42 during midday trading on Friday, reaching $143.83. 11,506,790 shares of the stock traded hands, compared to its average volume of 7,334,026. The stock’s fifty day moving average is $147.07 and its 200-day moving average is $143.86. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock has a market cap of $379.43 billion, a P/E ratio of 19.03, a PEG ratio of 3.13 and a beta of 0.70. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The company had revenue of $20.69 billion during the quarter, compared to analyst estimates of $19.48 billion. During the same period in the prior year, the company earned $2.10 earnings per share. The firm’s revenue was up 3.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 7.68 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.01 per share. The ex-dividend date of this dividend was Friday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 dividend on an annualized basis and a yield of 2.81%. Johnson & Johnson’s dividend payout ratio is 46.54%.

A number of equities analysts have commented on JNJ shares. Credit Suisse Group reaffirmed a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a research note on Tuesday, April 28th. SVB Leerink dropped their target price on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Morgan Stanley boosted their price target on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Citigroup boosted their price target on Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Finally, Bank of America upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price objective for the company from $150.00 to $175.00 in a research report on Wednesday, April 22nd. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $163.47.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Cost of Debt

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.